Ravi Salgia to Antibodies, Bispecific
This is a "connection" page, showing publications Ravi Salgia has written about Antibodies, Bispecific.
Connection Strength
0.224
-
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
Score: 0.224